HIV-Mycobacterium Tuberculosis Co-Infection Dynamics

The co-infection of HIV and Mycobacterium tuberculosis represents a major global health challenge, with each pathogen exacerbating the progression of the other. HIV undermines host defence by depleting CD4+ T lymphocytes and promoting chronic immune activation, which compromises the formation and maintenance of granulomas that normally contain latent M. tuberculosis. Conversely, tuberculosis drives inflammation and immune cell recruitment that can accelerate HIV replication and further CD4+ T-cell loss. This bidirectional synergy heightens the risk of latent TB reactivation, accelerates progression to active disease and increases mortality. Clinical presentation in co-infected individuals is often atypical, complicating diagnosis and delaying effective treatment. Underlying mechanisms include cytokine imbalances, macrophage dysfunction and immune exhaustion. Addressing this syndemic demands integrated diagnostic strategies, optimised combination therapies that minimise drug–drug interactions and the development of host-directed treatments. Advances in animal and ex vivo models are clarifying pathogen interplay and informing vaccine design, while coordinated global efforts are essential to reduce the toll of HIV–TB co-infection.

Research from Nature Portfolio

A foundational investigation using a humanised mouse model has illuminated early interactions between HIV and M. tuberculosis. In dual-infected animals, HIV-infected cells were found at sites of mycobacterial inflammation, eliciting a heightened pro-inflammatory cytokine signature. This response disrupted granuloma architecture, promoted neutrophil accumulation and led to increased mycobacterial burden and dissemination. These findings demonstrate that HIV exacerbates pulmonary pathology by undermining granuloma integrity and amplifying bacterial replication.

HIV-Mycobacterium Tuberculosis Co-Infection Dynamics publication trend

The graph below shows the total number of articles in hiv-mycobacterium tuberculosis co-infection dynamics across all publications each year (not limited to Nature Index journals).

Technical terms

Co-infection: Simultaneous infection of a host by HIV and Mycobacterium tuberculosis.

Granuloma: Organised aggregate of immune cells that walls off M. tuberculosis to prevent dissemination.

Antiretroviral therapy (ART): Combined medication regimen designed to suppress HIV replication and maintain immune function.

Immunosenescence: Age-related or infection-driven decline in immune system responsiveness.

Cytokine: Signalling protein released by immune cells to regulate inflammation and immune responses.

References

1. Mycobacterium tuberculosis EspR modulates Th1-Th2 shift by transcriptionally regulating IL-4, steering increased mycobacterial persistence and HIV propagation during co-infection. Frontiers in Immunology (2023).
2. Uncovering the Bronchoalveolar Single-Cell Landscape of Patients With Pulmonary Tuberculosis With Human Immunodeficiency Virus Type 1 Coinfection. The Journal of Infectious Diseases (2024).
3. HIV–TB Coinfection: Current Therapeutic Approaches and Drug Interactions. Viruses (2024).
4. Pulmonary Tuberculosis in Humanized Mice Infected with HIV-1. Scientific Reports (2016).